( MENAFN - EIN Presswire) Chest Freezers Global market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033 The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-for a limited time only! LONDON, GREATER LONDON, UNITED KINGDOM, December 13, 2024 /EINPresswire / -- The Business Research Company's Early Year-End Sale! Get up to 30% off detailed market research reports-limited time only! What Is The Anticipated Growth Rate and Market Size of the Global Chest Freezers Market? The chest freezers market size has seen a significant expansion in recent years. The market is projected to grow from $16.31 billion in 2023 to $18.36 billion in 2024, demonstrating a compound annual growth rate CAGR of 12.6%. The growth during the historical period can be attributed to the rising demand in developing economies, growth in small and medium enterprises, consumer preference for bulk purchasing, increasing focus on food waste reduction, and the expansion of e-commerce. Preview The Global Chest Freezers Market Report: What Does The Future Hold For The Chest Freezers Market? The chest freezers market size is poised for rapid growth in the upcoming years. The market is projected to reach $29.72 billion by 2028, expanding at a compound annual growth rate CAGR of 12.8%. This growth during the forecast period can be attributed to the increasing demand for frozen food, the rise in disposable income, the development of cold storage infrastructure, growing urbanization, migration to cities and the growth of the retail sector. Pre-order The Chest Freezers Global Market Report: What Are The Key Drivers Of The Chest Freezers Market? The rise in demand for frozen food products is anticipated to fuel the growth of the chest freezer market. Frozen food products, preserved by freezing to retain freshness and nutrients, have a longer shelf life for later consumption. The convenience, extended shelf life, and increasing consumer preference for ready-to-eat meals are fueling the demand for frozen food products, making chest freezers essential for optimal long-term storage which maintains the quality, safety, and extended shelf life of frozen items. Which Market Leaders Are Driving The Growth of the Chest Freezer Market? Major players in the chest freezers market include LG Electronics, Midea America Corp., Whirlpool Corp., Sharp Corporation, Liebherr-International GmbH, Electrolux Group, Westinghouse Electric Corp., The Middleby Corp., Dometic Group AB, and more. These major players have been crucial in driving market growth and will continue to play a significant role in its expansion. What Key Trends Are Impacting The Chest Freezer Market? Major companies in the chest freezer market are centered around developing and launching innovative products, offering flexibility to switch between freezer and refrigerator modes, to maintain their competitive edge. The future of cold storage is about to transform through technological innovation, a focus on sustainability, and an expanding market influenced by the consumer demand for frozen goods. How Is The Global Chest Freezer Market Segmented? 1 By Type: 500 And Above Liters, 300 To 500 Liters, 200 To 300 Liters, 200 And Below Liters 2 By Distribution Channel: Online, Offline 3 By Energy Efficiency: High, Medium, Low 4 By Door Type: Solid Door, Glass Door 5 By Application: Retail, Hospitality, Food And Beverage Processing, Cold Storage And Warehouses, Healthcare, Research and Laboratories, Residential, Other Applications What Does The Regional Analysis Tell Us About The Chest Freezer Market? In 2023, North America was the largest region in the chest freezers market. However, Asia-Pacific is expected to be the fastest-growing region in the forthcoming period. The regions covered in the chest freezers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Browse more similar reports- Congenital Heart Disease (CHD) Global Market Report 2024 Esophageal Catheters Global Market Report 2024 High-Frequency Chest-Wall Oscillation Devices Global Market Report 2024 About The Business Research Company Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game. Contact us at: The Business Research Company: Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at ... Follow us on: LinkedIn: YouTube: Global Market Model: global-market-model Oliver Guirdham The Business Research Company +44 20 7193 0708 email us here Visit us on social media: Facebook X LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. MENAFN12122024003118003196ID1108988684 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.None
Implements INDATA SaaS on a Front-to-Back Office Basis delivered via iPM Private Cloud GREENWICH, Conn. , Dec. 12, 2024 /PRNewswire/ -- INDATA , a leading industry provider of cloud-native, SaaS-based solutions for buyside firms, today announced that Paradigm Capital Management (PCM) is live with INDATA's Software-as-a-Service for Front, Middle and Back Office . With a three-decade history of small-cap investing, Paradigm Capital Management, based in Albany, NY employs a disciplined, bottom-up approach with an emphasis on fundamental analysis and extensive management contact. Paradigm manages $1.8 billion in AUM and offers a range of products including institutional separately managed accounts, proprietary mutual funds, and private wealth via hedge funds and LP's. Paradigm is using the INDATA system for a range of functions including trade order management (OMS), Portfolio Accounting , Performance and Reporting, including managed services for streamlined reconciliation. "We are very pleased to have Paradigm Capital Management as a client. We look forward to partnering with Paradigm on their ongoing needs," commented David Csiki , President of INDATA. About INDATA ® INDATA is a leading specialized provider of SaaS (Software-as-a-Service), technology and managed outsourcing services for buyside firms, including trade order management (OMS), portfolio management, compliance, portfolio accounting and front-to-back office. INDATA iPM Portfolio Architect AITM is the industry's first portfolio construction, modeling, rebalancing and reporting tool based on AI, and Machine Learning. INDATA's iPM – Intelligent Portfolio Management® technology platform allows end users to efficiently collaborate in real-time across the enterprise and contains the best of class functionality demanded by sophisticated institutional investors, wealth managers, and hedge funds. The company's mission is to provide clients with cutting edge technology products and services to increase trading and operational efficiency while reducing risk and administrative overhead. INDATA provides software and services to a variety of buyside clients including asset managers, registered investment advisors, banks and wealth management firms, pension funds and hedge funds. Assets under management range from under $1 billion to more than $100 billion across a variety of asset classes globally. For more information, visit www.indataipm.com Media Contact: David Csiki , dave@indataipm.com View original content: https://www.prnewswire.com/news-releases/paradigm-capital-management-live-with-indata-302330839.html SOURCE INDATA
Swiss National Bank increased its stake in shares of Lantheus Holdings, Inc. ( NASDAQ:LNTH – Free Report ) by 0.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 135,354 shares of the medical equipment provider’s stock after purchasing an additional 500 shares during the period. Swiss National Bank owned 0.19% of Lantheus worth $14,855,000 as of its most recent SEC filing. A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Lantheus by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after purchasing an additional 389,828 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock worth $182,999,000 after purchasing an additional 796,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after purchasing an additional 19,071 shares in the last quarter. Swedbank AB lifted its holdings in Lantheus by 21.1% during the 3rd quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares in the last quarter. Finally, Boston Partners raised its holdings in shares of Lantheus by 21.2% in the 1st quarter. Boston Partners now owns 681,281 shares of the medical equipment provider’s stock valued at $42,696,000 after acquiring an additional 119,156 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock. Lantheus Trading Up 3.7 % Shares of Lantheus stock opened at $90.52 on Friday. The firm has a market capitalization of $6.29 billion, a PE ratio of 15.06 and a beta of 0.51. The business’s 50-day moving average price is $103.43 and its 200-day moving average price is $96.53. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. Analyst Upgrades and Downgrades Check Out Our Latest Stock Report on LNTH Lantheus Company Profile ( Free Report ) Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. Further Reading Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. ( NASDAQ:LNTH – Free Report ). Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter .
PARADIGM CAPITAL MANAGEMENT LIVE WITH INDATAUS stocks tread water in thin trade, benchmark US yield ekes out new high
BOZEMAN, Mont. (AP) — Adam Jones ran for 197 yards and two touchdowns and Montana State ran over Montana 34-11 on Saturday to reclaim the Brawl of the Wild trophy. The Bobcats (12-0, 8-0 Big Sky Conference) wrapped up the 123rd meeting in this rivalry with 420 yards, 326 on the ground. Montana State capped its first unbeaten season and can match the school record for consecutive wins with a playoff win in two weeks. The Bobcats, ranked second in the FCS coaches poll, should be the top seed in the playoffs after top-ranked North Dakota State lost its finale to fifth-ranked South Dakota. Montana (8-4, 5-3), ranked 10th, is expected to add to its record 27 FCS playoff appearances but will not have a first-round bye in the 24-team bracket. Montana State quarterback Tommy Mellott was 6-of-12 passing for 94 yards with a touchdown in poor conditions and added 50 yards and a touchdown on the ground. He has helped the Bobcats score at least 30 points in every game this season Mellott had a 5-yard touchdown run on MSU's first possession and Mellott found Jones for a 35-yard touchdown early in the second quarter for a 14-3 lead. Myles Sansted had two field goals in the final two minutes, including a 49-yarder as time expired for a 20-3 halftime lead. Jones dominated the second half and scored two short touchdowns. Eli Gillman scored on a 1-yard run for Montana's touchdown between the Jones' touchdowns. The Grizzlies had just 234 yards and went 2 of 12 on third down. AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football . Sign up for the AP’s college football newsletter: https://apnews.com/cfbtop25Ravens QB Jackson leads first NFL Pro Bowl fan voting resultsAP Trending SummaryBrief at 5:34 p.m. EST
— BIRTH NAME: James Earl Carter, Jr. — BORN: Oct. 1, 1924, at the Wise Clinic in Plains, Georgia, the first U.S. president born in a hospital. He would become the first president to live for an entire century . — EDUCATION: Plains High School, Plains, Georgia, 1939-1941; Georgia Southwestern College, Americus, Georgia, 1941-1942; Georgia Institute of Technology, Atlanta, 1942-1943; U.S. Naval Academy, Annapolis, Maryland, 1943-1946 (class of 1947); Union College, Schenectady, New York, 1952-1953. — PRESIDENCY: Sworn-in as 39th president of the United States at the age of 52 years, 3 months and 20 days on Jan. 20, 1977, after defeating President Gerald R. Ford in the 1976 general election. Left office on Jan. 20, 1981, following 1980 general election loss to Ronald Reagan. — POST-PRESIDENCY: Launched The Carter Center in 1982. Began volunteering at Habitat for Humanity in 1984. Awarded Nobel Peace Prize in 2002. Taught for 37 years at Emory University, where he was granted tenure in 2019, at age 94. — OTHER ELECTED OFFICES: Georgia state senator, 1963-1967; Georgia governor, 1971-1975. — OTHER OCCUPATIONS: Served in U.S. Navy, achieved rank of lieutenant, 1946-53; Farmer, warehouseman, Plains, Georgia, 1953-77. — FAMILY: Wife, Rosalynn Smith Carter , married July 7, 1946 until her death Nov. 19, 2023. They had three sons, John William (Jack), James Earl III (Chip), Donnel Jeffrey (Jeff); a daughter, Amy Lynn; and 11 living grandchildren and 14 great-grandchildren. Source: Jimmy Carter Library & Museum
Jones, Mellott help Montana State run over Montana 34-11
Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.CORAL GABLES, Fla. (AP) — Maria Gakdeng tied her season high with 21 points and grabbed a season-best 12 rebounds, Alyssa Ustby added 19 points and 13 boards and the No. 17 North Carolina women beat Miami 69-60 on Sunday for their third consecutive win. North Carolina (13-2, 1-1 ACC) lost its conference opener to No. 13 Georgia Tech on Dec. 15 before nonconference wins against Florida and Norfolk State. Gakdeng made 7 of 11 from the field and 7 of 10 from the free-throw line. Indya Nivar finished with 11 points, five assists and three steals for the Tar Heels. Miami (11-2, 1-1) had its four-game win streak snapped. Gakdeng made a layup with 6:14 left in the first quarter that gave North Carolina the lead for good and Ustby followed with a 3-pointer to spark a 9-0 spurt that made it 16-7 about 2 minutes later. The Tar Heels scored eight of the first 10 second-quarter points to push their lead to 13 with 7:25 left in the second quarter before Miami scored the final seven points to trim its deficit to 39-29 at halftime. Jasmyne Roberts hit a 3-pointer for the Hurricanes that made it a seven-point game with 8:11 left in the third quarter but they got no closer. Nivar made a layup with 5:16 remaining until the fourth that made it 48-38 and UNC led by double figures until a 3-pointer by Roberts capped the scoring in the closing seconds. Hannah Cavinder led Miami with 19 points, 11 rebounds and five assists. Roberts made four 3-pointers and also scored 19 points, 14 in the second half. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP women’s college basketball: https://apnews.com/hub/ap-top-25-womens-college-basketball-poll and https://apnews.com/hub/womens-college-basketballNasdaq, S&P 500 close at record highs Monday with tech-related shares